Technical Analysis for ABEO - Abeona Therapeutics Inc.

Grade Last Price % Change Price Change
grade D 3.24 1.25% 0.04
ABEO closed up 1.25 percent on Thursday, September 19, 2019, on 1.49 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical ABEO trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Stochastic Reached Overbought Strength 1.25%
Wide Bands Range Expansion 1.25%
Overbought Stochastic Strength 1.25%
50 DMA Support Bullish 10.96%
1,2,3 Pullback Bullish Bullish Swing Setup 10.96%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 10.96%
Outside Day Range Expansion 10.96%

Older signals for ABEO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Abeona Therapeutics, Inc., formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for severe and rare diseases. The Company's lead program includes adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB). Its product pipeline includes ABO-101 (sc AAV9 NAGLU), which is used for the treatment of MPS III B; ABO-102 (sc AAV9 SGSH), which is used for the treatment of MPS III A; ABO-201 (sc AAV9 CLN3), which is used for the treatment of Juvenile Batten Disease (JBD); ABO-301 (AAV LK19 FANCC), which is used for the treatment of Fanconi Anemia (FA), and clustered, regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) gene editing, which is used for treatment of other rare blood diseases. The Company offers two platforms: Salt Diafiltration (SDF) Process and Polymer Hydrogel Technology (PHT).
Biotechnology Biology Emerging Technologies Gene Therapy Molecular Biology Genetics Genetic Engineering Genome Editing Adeno Associated Virus AAV Cas9 CRISPR Severe And Rare Diseases
Is ABEO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 14.1
52 Week Low 1.46
Average Volume 1,240,405
200-Day Moving Average 5.8663
50-Day Moving Average 2.828
20-Day Moving Average 2.6145
10-Day Moving Average 3.074
Average True Range 0.3102
ADX 46.12
+DI 34.0174
-DI 14.7803
Chandelier Exit (Long, 3 ATRs ) 2.5794
Chandelier Exit (Short, 3 ATRs ) 2.3906
Upper Bollinger Band 3.8267
Lower Bollinger Band 1.4023
Percent B (%b) 0.76
BandWidth 92.729011
MACD Line 0.1372
MACD Signal Line 0.0442
MACD Histogram 0.093
Fundamentals Value
Market Cap 130.53 Million
Num Shares 40.3 Million
EPS -0.61
Price-to-Earnings (P/E) Ratio -5.31
Price-to-Sales 831.55
Price-to-Book 7.87
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.83
Resistance 3 (R3) 3.85 3.68 3.73
Resistance 2 (R2) 3.68 3.53 3.67 3.69
Resistance 1 (R1) 3.46 3.44 3.57 3.44 3.66
Pivot Point 3.29 3.29 3.35 3.28 3.29
Support 1 (S1) 3.07 3.14 3.18 3.05 2.82
Support 2 (S2) 2.90 3.05 2.89 2.79
Support 3 (S3) 2.68 2.90 2.75
Support 4 (S4) 2.66